Form 4 for LLY Lilly (Eli)
Accepted 2026-02-03 00:00:00 ET · period of report 2026-02-01 · accession 0001661254-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-03 | 2026-02-01 | LLY | Van Naarden Jacob | EVP, Pres LLY Oncology, HdCorpBD | F - Tax | $1,037.15 | -1,909 | 22.8K | -8% | -$1.98M |
| D | 2026-02-03 | 2026-02-01 | LLY | Van Naarden Jacob | EVP, Pres LLY Oncology, HdCorpBD | M - OptEx | $0.00 | +4,108 | 24.7K | +20% | $0 |
| D | 2026-02-03 | 2026-02-01 | LLY | Van Naarden Jacob | EVP, Pres LLY Oncology, HdCorpBD | M - OptEx | $0.00 | -4,108 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-01 | F | D | 1,909.38 | $1,037.15 | 22,760.61 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-01 | M | A | 4,108 | $0.00 | 24,669.99 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2026-02-01 | M | D | 4,108 | $0.00 | 0 | D | — · 2026-02-01 to 2026-02-01 | 4,108 Common Stock | (F2) Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. |